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ABSTRACT
Objectives To undertake a process evaluation of 
an adherence support intervention for people with 
cystic fibrosis (PWCF), to assess its feasibility and 
acceptability.
Setting Two UK cystic fibrosis (CF) units.
Participants Fourteen adult PWCF; three professionals 
delivering adherence support (‘interventionists’); five multi- 
disciplinary CF team members.
Interventions Nebuliser with data recording and 
transfer capability, linked to a software platform, 
and strategies to support adherence to nebulised 
treatments facilitated by interventionists over 5 months 
(± 1 month).
Primary and secondary measures Feasibility and 
acceptability of the intervention, assessed through 
semistructured interviews, questionnaires, fidelity 
assessments and click analytics.
Results Interventionists were complimentary 
about the intervention and training. Key barriers to 
intervention feasibility and acceptability were identified. 
Interventionists had difficulty finding clinic space 
and time in normal working hours to conduct review 
visits. As a result, fewer than expected intervention 
visits were conducted and interviews indicated this 
may explain low adherence in some intervention arm 
participants. Adherence levels appeared to be >100% 
for some patients, due to inaccurate prescription 
data, particularly in patients with complex treatment 
regimens. Flatlines in adherence data at the start of 
the study were linked to device connectivity problems. 
Content and delivery quality fidelity were 100% and 
60%–92%, respectively, indicating that interventionists 
needed to focus more on intervention ‘active 
ingredients’ during sessions.
Conclusions The process evaluation led to 14 key 
changes to intervention procedures to overcome barriers 
to intervention success. With the identified changes, it is 
feasible and acceptable to support medication adherence 
with this intervention.
Trial registration number ISRCTN13076797; Results.
BACKGROUND
Cystic fibrosis (CF) is a life- threatening, 
inherited condition affecting over 90 000 
people worldwide, primarily of Northern 
European ancestry.1 Median survival for 
people with cysticfibrosis (PWCF) is esti-
mated at 31 years2–6 with progressive lung 
function decline, caused by regular infection 
and damage to airways, being one of the main 
disease features.2
Preventative medications preserve lung 
function and reduce exacerbations.7–13 Low 
adherence to these medications is problem-
atic as this predicts exacerbations requiring 
intravenous antibiotics (IVAB).14 15 Exacer-
bations of this nature carry a risk of systemic 
side effects of both increased mortality,16 17 
and cost of care.18–20 In 2012, the total spend 
on CF in the UK was estimated to be £100 
million, with £30 million spent on inhaled 
antibiotics and mucolytics21; the UK CF popu-
lation received 1 71 907 days of IVAB with 93 
455 days received in hospital, costing an esti-
mated £27 million.22
Self- reported adherence to inhaled ther-
apies underestimates objectively measured 
adherence, with rates of 80% and 36% 
recorded, respectively23 and systematic data 
Strengths and limitations of this study
 ► This is a detailed evaluation of the feasibility of an 
adherence support system for people with cystic 
fibrosis.
 ► The use of mixed- methods provided indepth under-
standing of the processes involved in delivering the 
service, its value and factors that might influence its 
use, implementation and success.
 ► This was a small, two- centre study.
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collection suggests objective adherence to be closer to 
30%.24 As a result, clinicians are currently unable to iden-
tify PWCF with low adherence, in order to provide addi-
tional support. Hitherto, the most objective surrogate 
measure of adherence has been the medicines possession 
ratio (MPR). However, based on the experience of a CF 
service in Leeds, UK, MPR rates of 63%25 considerably 
overestimate adherence compared with nebuliser down-
load data of 36%.26
Treatment burden has long been recognised as a key 
barrier to medication adherence in CF,27 and reducing 
treatment burden is a key research priority for PWCF 
and clinicians, identified by the Cystic Fibrosis Foun-
dation and the James Lind Alliance.28 29 In response, a 
complex intervention was developed to support inhaled 
medication adherence in PWCF.30 This article presents 
the results of a process evaluation that was undertaken 
alongside a pilot randomisedcontrolled trial (RCT), the 
objectives of which were to determine the feasibility of a 
full- scale RCT.30 Here, we describe the resultant changes 
made to intervention procedures prior to that full- scale 
RCT.31 The specific objectives of the process evaluation 
were:
1. To triangulate qualitative and quantitative data col-
lected on intervention inputs, engagement, activities 
and contextual factors, alongside immediate and inter-
mediate outcomes recorded in the feasibility study, to 
understand and identify potential barriers to interven-
tion implementation and success.
2. To document and use these findings to guide chang-
es to intervention procedures, ahead of a future, full- 
scale RCT.
METHODS
The wider feasibility study
The process evaluation forms one part of a wider pilot 
study, which also assessed the feasibility of RCT proce-
dures and mechanisms of action (reported elsewhere30 32). 
The pilot RCT consisted of 33 intervention patients and 
31 control patients. Three trained interventionists in two 
UK CF centres delivered the intervention to PWCF in the 
intervention arm and followed them up for 5 months, ±1 
month.
Intervention description
The complex intervention to support adherence in CF 
was developed to enable PWCF to manage adherence to 
nebulised medication, with a view to shifting CF treatment 
from rescue in hospital settings to prevention, managed 
in the community. The full intervention development 
process is described in a separate article.30
The complex intervention consists of four key elements: 
the eTrack, CFHealthHub (CFHH) server, the CFHH 
Figure 1 Logic model. CF, cysticfibrosis; CHAOS, Confusion, Hubbub and Order Scale; COM- BMQ, Capability Opportunity 
Motivation Behaviour Beliefs about Medicines Questionnaire; FEV1,forced expiratory volume in 1 second; HRQoL, Health- 
Related Quality of Life; MDT, multidisciplinary team.
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Apps and the manualised behavioural intervention. A 
logic model (figure 1) was produced to reflect, in detail, 
constructs and processes by which the intervention was 
expected to function; this is in terms of inputs, engage-
ment, activities and outcomes. The logic model’s hashed 
numbers (#1, #2, etc) provide a reference for linking 
intervention materials and processes to logic model 
constructs in figure 1.
The eTrack (PARI Pharma GmbH, Starnberg, Germany; 
#4) is a microchipped nebuliser, enabling real- time moni-
toring of adherence to nebulised medications. Time-
stamped records of medications administered via the 
eTrack are sent to a 2net Hub (Qualcomm, San Diego, 
USA; #5) which transmits data to PARI.
Real- time inhalation data are received by the CFHH 
server infrastructure, stored securely and used for display 
in both a web- based interface and a mobile app (#6, see 
figure 2). Each of these displays adherence data along-
side tools to support behaviour change and educational 
content.33 Educational modules within CFHH include: 
‘What is Cystic Fibrosis?’; ‘What does my IV treatment 
do?’; ‘I'm not convinced that my nebuliser treatment 
works’; ‘What does my nebuliser treatment do and why 
should I take it?’; ‘Why is it important that I do my nebu-
liser treatment every day?’; and, ‘I have concerns about 
my nebuliser treatments’. The nebuliser medication 
information displayed to the user in these sections are 
tailored to them based on a baseline assessment of moti-
vation, so as not to overwhelm them.
Participants and their interventionists had access to 
adherence displays for monitoring (#13, #19, #20) and 
other CFHH content (#21–#26), such as education 
about treatments (#21) and problem solving in the face 
of adherence barriers (#26). Interventionists would use 
CFHH to facilitate delivery of manualised behavioural 
intervention sessions (#8, #17).
Interventionists (n=3) included a clinical psychologist, a 
physiotherapist and a social worker. They received specific 
training to deliver the manualised intervention sessions 
(#9). Training was delivered over 2 days, in face- to- face work-
shops. This was supplemented by online learning modules 
and a further 4- week training schedule. Interventionists 
were assessed with online theory tests and in a competency 
assessment which examined intervention delivery within the 
first five sessions.
Sessions were delivered either face- to- face or remotely, 
on a one- to- one basis. All intervention arm participants 
received an initial intervention visit and a minimum of 
one additional review visit over the period of the study 
(#18). The content of sessions varied by participant 
reported motivation; sessions for those with low motiva-
tion were tailored to promote relationship/confidence 
building and to support the participant in the exploration 
of relevant CFHH educational and information mate-
rial (#21, #22). Relevant material could be added to the 
participant’s personalised ‘Toolkit’. Sessions conducted 
with participants displaying higher motivation would also 
involve supporting the participant to set personalised 
adherence goals (#23, #24), and to make action plans 
(#25) and engage in problem solving including making 
coping plans where relevant (#26).
Figure 2 The digital platform. CFHH, CFHealthHub; PWCF, peoplewith cystic fibrosis.
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Design
A mixed- methods approach was used for the process eval-
uation. Although this pragmatic case study34 35 primarily 
works at the level of the programme, we also present a 
nested multiple case design, with cases at the level of the 
PWCF, and two embedded units of analysis—interviews 
with intervention participants and trial data.
Data sources
Quantitative and qualitative data sources were triangu-
lated to address process evaluation objectives. These are 
described using hashed numbers to relate data sources 
to aspects of the logic model (figure 1) for which they 
contributed data.
Qualitative data included verbal reports from project 
staff (#1. #2, #10, #16); semistructured interviews with 
interventionists and participants in the intervention and 
control arms of the pilot RCT (#8, #9, #12, #13, #14, #15, 
#16, #17, #19, #20, #21); minutes of meetings (#3); emails 
(#4), website development reports (#6); and fidelity 
assessments (#17). Semistructured interviews, conducted 
face- to- face, were digitally audio- recorded and tran-
scribed verbatim. The median length of interviews was 30 
min (range 11–87) for PWCF, 86 min (63–102) for inter-
ventionists and 62 min (51–66) for CF team members.
Quantitative data included implementation log entries 
and data management reports (#3), questionnaire data 
derived from secondary clinical outcome measures 
described in table 1 (#7, #28, #29, #30, #31, #32, #33); 
an interventionist- completed structured questionnaire 
on interventionist confidence post- training (#9); struc-
tured interventionist fidelity assessments in which audio- 
recordings of intervention sessions were coded using 
a fidelity scoring system which assessed whether each 
component of the intervention was delivered and the 
quality of that delivery (#11, #17); CFHH click analytics 
(#13, #14, #15, #18, #20, #21, #22, #23, #24, #25, #26); 
session frequency and duration records (#15); and 
adherence data taken from CFHH (#35). Quantitative 
or descriptive data were collected for the 23 logic model 
constructs listed in this paragraph as part of the trial 
protocol, as described in table 1.
Sampling
Participants were recruited for semistructured interviews. 
Participants included intervention arm participants 
(n=14), interventionists (n=3, 0.8 whole- time equiva-
lents at each centre) and members of the wider, multi-
disciplinary CF team (n=5). Participants were purposively 
sampled based on site, age, gender, deprivation index, 
objective and subjective adherence levels (service users) 
or site and professional category (professionals). Inter-
ventionists were interviewed twice—at the beginning and 
end of the study—patients once. PWCF who consented to 
be approached for interview were contacted by letter or 
email and, subsequently, telephone or email depending 
on preference. Professionals were contacted directly by 
the study team.
Data analysis
We conducted a Framework analysis of interview tran-
scripts,36 within NVivo (QSR International) using 
multiple frameworks including the Theoretical Domains 
Framework,37 a process evaluation framework38 and the 
logic model (figure 1).
Using a modified triangulation protocol,39 we integrated 
qualitative and quantitative datasets at the programme and 
the case level.40 We used a joint display table41 to summarise 
datasets for 35 logic model constructs in the Inputs (n=12), 
Engagement (n=6), Activities (n=7), Immediate outcomes 
(n=6) and Intermediate outcomes (n=2) columns (figure 1). 
The fit of data integration was categorised as ‘confirmation’ 
(quantitative and qualitative data provided similar findings); 
‘expansion’ (the datasets addressed different or comple-
mentary aspects of the phenomenon); or ‘discordance’ 
(the datasets were contradictory).42 We described similar 
and unique contributions, made by the two datasets, to the 
research question.39
In the 14 intervention participants, for whom both 
qualitative and quantitative process data were available, 
we produced case profiles,43 triangulating qualitative 
data with individual- participant adherence run charts44 
(online supplemental file 01) and other quantitative 
process data (see online supplemental file 02 Study 
protocol, pp29–31). We worked abductively, moving 
between behaviour change theories45 46 and contextual 
observations, agreeing plausible hypotheses to explain 
patterns which could be tested in future work.47–50
We produced a case- ordered descriptive matrix,51 with 
cases ranked by average adherence during the last month 
of the study, to understand how processes and outcomes 
were mediated by local and individual conditions. Adher-
ence levels of >80% were assessed as high; 50%–80% 
moderate; <50% low.14 52 We theorised that high life 
chaos, as measured by the Confusion, Hubbub and Order 
Scale (CHAOS)53 and low motivation would be associated 
with low adherence. We used four measures to under-
stand motivation: (1) a single item, scored on a 1–7 Likert 
scale—‘I want to do all of my nebuliser treatment’ (moti-
vation); (2) a single item, scored on a 1–7 Likert scale, 
which asked, ‘I am confident I can do all of my nebuliser 
treatments’ (‘confidence’); (3) the necessities and (4) 
concerns 5- point subscales of the Beliefs about Medicines 
Questionnaire nebuliser- specific (BMQ) instrument.54 
Interventionists assessed the participant’s motivation to 
increase adherence on a 1 to 7 scale after discussion with 
the patient; adequate motivation was necessary before 
participants could make action plans and do problem- 
solving activities.
Approach taken to modifying the intervention
Modifications to the intervention fell into three catego-
ries: the software platform; other information technology 
(IT) infrastructure; and the manual and training. Iden-
tified problems and solutions were tabulated following a 
modified approach of that taken by Bugge et al.31 Digital 
platform development was reviewed regularly using the 
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Table 1 Quantitative data contributing to the understanding of logic model constructs
# Logic model column/construct Quantitative
Inputs   
  3 Prescription data CFHH; problems documented in implementation log.
  7 COM- BMQ questionnaire responses COM- BMQ, incorporating the Beliefs about Medicines 
Questionnaire (Nebuliser adherence),54 one additional belief 
item, one intention item, one confidence item, and a list of 
barriers.
  9 Interventionist training programme Structured questionnaire on interventionist confidence after 
training programme.
  11 Competency/fidelity assessment Structured instrument for the assessment of interventionist 
competence.
Engagement
  13 Clinicians accessing adherence data CFHH click analytics.
  14 Adherence data tracking CFHH click analytics.
  15 Participant accessing CFHH CFHH click analytics.
  17 CFHH Intervention sessions delivered according to 
manual (fidelity)
Project- specific structured fidelity assessment instrument.
  18 Initial session, and then review at each clinic visit CFHH click analytics.
Activities
  Intervention components for all participants
   20 Self- monitoring adherence CFHH click analytics.
   21 Tailored education about treatment CFHH click analytics.
   22 Tailored patient stories (videos) CFHH click analytics.
  Intervention components for those with adequate motivation
   23 Personalised goal- setting CFHH click analytics.
   24 Goal review CFHH click analytics.
   25 Personalised action plan CFHH click analytics.
   26 Tailored problem solving CFHH click analytics.
Immediate outcomes
  For all participants
   28 Acute awareness of adherence/increased Motivation Subjective adherence single question (self- report estimate of 
adherence as a percentage); COM- BMQ.
   29 Increased necessity and decreased concern COM- BMQ and PAM-13.127
   30 Increased self- efficacy/motivation COM- BMQ single question about confidence to adhere; PAM-
13.
  For those with adequate motivation
   31 Increased self- efficacy/motivation COM- BMQ single question about confidence to adhere; PAM-
13.
   32 Increased habit/reduced chaos SRBAI automaticity- specific subscale of the Self Report Habit 
index to capture habit- based behaviour patterns128; CHAOS 
6- item: measure of life chaos.53
   33 Reduced barriers No change in the group averages for The Beliefs about 
Medicines Questionnaire—specific (Nebuliser adherence, 
BMQ 21- item54).
Intermediate outcomes
  35 Increased adherence Nebuliser data (CFHH)
CFHH, CFHealthHub; CHAOS, Confusion, Hubbub and Order Scale; COM- BMQ, Capability Opportunity Motivation Behaviour 
Beliefs about Medicines Questionnaire; PAM-13, Patient Activation Measure 13; SRBAI, Self- Report Behavioural Automaticity 
Index.
6 Hind D, et al. BMJ Open 2020;10:e039089. doi:10.1136/bmjopen-2020-039089
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‘Must have, Should have, Could have, and Won't have 
but would like’ (MoSCoW),55 often used in agile software 
development.56 57
Patient and public involvement
Recruitment for the patient and public involvement 
(PPI) group was achieved by advertising within CF units 
and on the People in Research website, as well as via 
group members themselves. Cross- infection between 
PWCF58 was prevented by arranging meetings via telecon-
ference. The PPI group gave feedback on intervention 
data sharing policies, usability and presentation of the 
website/user guide. In addition, the PPI group piloted 
the participant information materials and one individual 
gave feedback on the trial protocol and interview guides 
(online supplemental file 02).
Ethics and al approval
The study received approval from London Brent 
Research Ethics Committee (16/LO/0356). The funder 
was not involved in the trial design, patient recruitment, 
data collection, analysis, interpretation, or presentation, 
writing or editing of the report or the decision to submit 
for publication. The corresponding author had full access 
to all the data in the study and had final responsibility for 
the decision to submit for publication.
RESULTS
In what follows, we address contextual factors that affected 
implementation and participant responses, then follow 
the columns (inputs, engagement, activities, immediate 
and intermediate outcomes) of the logic model. Online 
supplemental file 03, tables A–G summarises quantitative 
process outcomes for 14 case study participants, ranked 
by objective adherence at the end of the trial. Hashed 
numbers (#1, #2, etc) indicate cross references to the 
logic model (figure 1) and supporting evidence in online 
supplemental fle 04, which summarises data triangulation 
at the level of individual logic model constructs. Both 
qualitative and quantitative data were available for 13/34 
logic model constructs, providing confirmation of (n=2) 
or expansion on (n=11) inferences drawn from quanti-
tative data. A case- ordered descriptive matrix based on 
logic model columns (online supplemental file 05) and 
run charts annotated with key events (online supple-
mental file 01) provides an integrated analysis at the level 
of the participant for 14 ‘case studies’, cross referenced 
by participant numbers (R02/52, R01/54, etc).
Contextual factors affecting implementation and participant 
responses
The key factor affecting implementation was the mixed 
economy of CF drug delivery systems: the e- Flow (PARI 
Pharma GmbH, Starnberg, Germany); the iNeb (Philips 
Healthcare, Eindhoven, Netherlands); and a number of 
dry powder delivery systems. The e- Flow is the only device 
able to deliver all the wet nebulised drugs that are used 
in CF care. The e- Track we used in this trial was a version 
of the e- Flow developed to transfer time- stamped and 
date- stamped data. Most patients at site R01 used e- Flows; 
switching consenting participants over to the e- Track was 
generally unproblematic. The e- Flow’s competitor, the 
iNeb, cannot deliver aztreonam and requires double- 
chamber filling to deliver tobramycin, so it is not suitable 
for all patients. The data transfer version of the iNeb, 
the BiNeb, is a prototype for which limited numbers are 
available. We were unable to secure approval to integrate 
the BiNeb into CFHH in time to incorporate it into this 
study. At site R02 where iNebs were commonly used, 
those who were familiar with and liked the iNeb were less 
keen to swap to an alternative device; some who swapped 
to the e- Track, later wanted to move back to the iNeb. 
A minority of patients use dry powder delivery systems, 
none of which have data transfer versions. We were unsuc-
cessful in engaging any of the companies producing dry 
powders in time to get dry powder systems integrated 
into CFHH, meaning that dry powder users could not be 
recruited to this feasibility study. Making nebulisers with 
data recording and transfer capability available within 
hospitals following local delivery took prolonged engage-
ment with medical engineering departments to obtain 
local safety approvals. For more than one participant, the 
strength of their mobile data signal affected 2net Hub 
connectivity with the central server (Implementation log, 
19 October 2016).
Through meetings with site staff, the team identified 
a range of human factors that also affected implementa-
tion, in particular: the availability of out- patient rooms; 
the need to clean rooms after each consultation for cross- 
infection control purposes; and the expectation that, 
during hospital visits, outpatients will see the whole each 
member of the multidisciplinary team (MDT) separately. 
The struggle for clinic space and patient convenience 
resulted in more home visits than anticipated for consent 
and review meetings, informed by local lone- working 
policies. Reorganisation of one CF Centre, involving the 
transfer of patients from the care of one local hospital 
to another, had created discontent among some patients 
involved in the trial.
Inputs
The study chief investigator reported introducing local 
site investigators, centre directors and MDTs to CFHH 
(#1). Through case reports, he conveyed that relying 
on forced expiratory volume in 1 second, symptoms and 
body mass index for CF management alone is inadequate 
and that objective adherence data could help overcome 
the ‘lamppost syndrome’,59 also known as the ‘streetlight 
effect’60 61 or ‘drunkard’s search’ (p1162)—a type of avail-
ability bias.63 The chief investigator reported feeling that 
site investigators at both centres were fully bought in, but 
that one clinician (not an investigator) believed that the 
disparities between subjective and objective adherence23 
were overstated (#2).
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Interventionists entered prescription data into CFHH 
based on patient records and self- reported treatment 
regimen (#3). Occasionally, interventionists were slow 
to make monthly prescription checks when prompted 
by system alerts, resulting in apparent adherence levels 
of over 100%, traced to the use of alternating treatment 
regimens64 (Implementation Log, 1 December 2016, 
TMG minutes 10 January 2017). Nebulisers with data 
recording and transfer capability (#4), 2net Hubs (#5), 
the CFHH website and mobile application (#6), were 
made available (emails to project manager 20 May 2016, 
23 June 2016). The Capability Opportunity Motivation- 
Beliefs about Medicines Questionnaire (COM- BMQ—see 
online supplemental file 02)54 questionnaire data (#7) 
was collected in CFHH (online supplemental file 06, 
tables 1–22 and figures 1–9).
Interventionists were complimentary about the inter-
vention manual (#8) and highly satisfied with training, 
but suggested that future courses involved a case study 
approach, following a patient through the intervention 
to illustrate its different aspects (#9, online supplemental 
file 04). A member of the research team (MH) acted as an 
intervention mentor to interventionists (#10). Interviews 
(SD) and observations (MH, HC) identified differences 
in the way site investigators interacted with intervention-
ists, with one giving more intensive practical support, 
through weekly meetings and problem solving (not 
prescribed by the intervention), than the other. Fidelity 
data were collected on all three interventionists and the 
fidelity assessment instrument was modified before use 
in the full RCT (#11). During interviews, interventionists 
were enthusiastic about intervention processes (#12). As 
sites struggled to find space or time for consent/inter-
vention encounters in clinic, the study team requested 
an increase in the number of home visits (Implementa-
tion log 19 October 2016). As a result of initial problems 
in contacting participants and the need for flexibility in 
arranging meetings out of usual clinic hours, the study 
team requested flexible working in which the team 
worked 12:00 to 20:00 2 days a week (interviews & TMG 
minutes 29 November 2016).
Engagement
Interviews and click analytics showed that MDT members 
did not access adherence data (#13), aside from in the 
form of bar charts brought to MDT meetings by interven-
tionists. It is important to note that extending the use of 
CFHH to the MDT was not an objective of the trial and no 
training was given in this regard. Click analytics showed 
that interventionists tracked adherence (#14). Of 14 case 
study participants, 3 did not contribute complete adher-
ence data: R02/42 and R02/02 withdrew, while R02/03 
was lost to follow- up. In other participants, flatlines in 
adherence data caused concern (online supplemental file 
01). Flatlines at the beginning of the study (eg, R01/39, 
R01/48) indicated technical problems with pairing nebu-
lisers and hubs. Flatlines at the end of the study period 
(eg, R01/42, R01/44, R02/12) were confirmed as the 
genuine recording of non- adherence through the use 
of adherence data beyond the end of the study period, 
interview data, self- report subjective adherence and the 
Medication Adherence Data-3 (online supplemental file 
03, table F).
Click analytics showed the median number of partici-
pant CFHH sessions was three (#15, online supplemental 
file 03, table C). Of those with low usage, initial technical 
problems (R01/02, R01/48) and initial lack of availability 
of a mobile application (#6) were potential contributing 
factors. Some case study participants showed moderate 
(R02/52, R01/54 and R01/40: 9–13 sessions) or high use 
(R02/12 and R01/42:>40 sessions). Push notifications—
user- defined messages from the server which give partic-
ipants congratulations or reminders about adherence 
behaviour—were not available in the pilot trial (#16).
Based on fidelity assessment of intervention session 
recordings, the content fidelity of face- to- face interactions, 
was excellent (100%)—with all aspects delivered as per the 
manual (#17). Delivery quality fidelity was more variable 
(60%–92%). The generation of goals and action plans 
was sometimes too directive rather than negotiated and 
supportive. Interviews demonstrated that assessing the 
true level of motivation to adhere to treatment was chal-
lenging; sometimes those with insufficient intrinsic moti-
vation (eg, R01/48, R01/54 and R02/03) were assessed as 
having sufficient motivation and inappropriately tasked 
with setting and reviewing goals, making action plans and 
problem solving (see below #23–#26). These individuals 
were variably motivated by wanting to prove themselves 
to MDT members, who had doubted their adherence 
(R01/49 and R01/54, online supplemental file 05), or by 
helping the research:
I made that special effort ‘cause I was taking part in 
this trial…I didn’t see how it was going to make me 
better. (R01/48)
Interaction with these individuals should have been 
confined to relationship- building and trust- building. 
Fidelity assessment of recordings identified that, in inter-
actions with the adequately motivated, the focus was 
not always on the most active ingredients—goal- setting, 
action planning (habit formation) and problem solving/
coping planning. Participant run charts (online supple-
mental file 01) revealed a disparity in whether and when 
review visits happened (#18).
Activities
In interviews, CF team clinicians (as distinct from the 
interventionists) confirmed they were not monitoring 
adherence as part of usual care (#19). Participant R01/02 
complained that the research focus on adherence was 
‘parallel rather than integrated’ with mainstream clinical 
management. However, the intervention was designed to 
be interventionist delivered allowing individual rando-
misation in a system without contamination of controls 
rather than an intervention aimed at achieving system 
change which would have required a cluster trial design. 
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Participants’ clicks (median 11) on the CFHH ‘How 
am I doing?’ (run charts) page sometimes related to a 
limited number of sessions. In interviews, one moderately 
frequent user (R01/54) only accessed this page to check 
their data were uploading. Other moderate/frequent 
users described this page as important for adherence self- 
monitoring (#20), even when their grasp of their own 
adherence was poor (R01/49).
In interviews with participants, for tailored education 
about treatment (#21), participants accessed particular 
education pages for specific issues, such as nebuliser 
malfunction, which was viewed as, ‘more down to earth’ 
than technical manuals. In particular a video about the 
treatment action of Dornase alfa, was often praised, as 
a means of educating others about CF; ‘Talking heads’ 
videos (in these videos people with CF described strate-
gies for successful nebuliser use, #22) divided opinion: for 
some, the opportunity for social comparison65 provided 
relief and reassurance; those who were less appreciative 
were those who found comparisons with people healthier 
than themselves could make them feel as though they 
were not doing well and comparisons with those less 
healthy could make them fearful of the future.
Other activities (#23–#26 on the logic model) required 
participants to have adequate levels of motivation. Inter-
ventionists classified all but one case study participant 
(R01/44) as having adequate motivation (online supple-
mental file 03, table B) and therefore eligible for further 
tailored intervention. But, as detailed above (see #17 in 
the engagement section), this was sometimes based on 
inadequate discussion with the participants. In inter-
views, participants generally reported setting goals (#23), 
but fidelity assessment showed that goals were sometimes 
formulated by interventionists rather than by partic-
ipants (see #17). The mean number of review sessions 
(#24) over 5 months was 1 (online supplemental file 03, 
table E); this was fewer than intended, likely reflecting a 
failure of the study team to set appropriate expectations 
and a lack of time created by the high pace of recruit-
ment (problem log entries: 31 January 2017; 13 February 
2017). Two individuals (R01/39 and R01/40) received 
their first face- to- face session with an interventionist over 
halfway through the study period (online supplemental 
file 01). CFHH action plan (#25), problem solving and 
coping plan (#26) pages were accessed a median of two, 
three and one times, respectively (online supplemental 
file 03, table E). Interviews data suggest action/coping 
plans were completed during intervention visits but not 
accessed by participants otherwise. In interviews, some 
participants said they were reassured by the presence of, 
and sometimes reported insights from, problem- solving 
modules, such as what to do when going on holiday. 
However, the use of action plans was disliked by some 
participants who found writing down the action plans like 
‘going back to school’. This dislike at least partly reflected 
the generation of action and coping plans by interven-
tionists rather than by the participants themselves (see 
#17).
Immediate outcomes
The pilot was not designed to disseminate the interven-
tion across the centre and with minimal monitoring by 
professionals within the wider CF team (see #19) routine 
medical care was not informed by adherence (#27). 
Unsurprisingly, given the lower than expected face- to- face 
contact (#18, #24), intervention arm group averages for 
immediate (process) outcomes (#28–33) changed little 
over 5 months, with the exception that there was a mean 
reduction of 1.84 (SD 3.44) barriers to adherence per 
person (#33), which could be the outcome of problem 
solving and education about treatment processes (online 
supplemental file 03, table F). Frequent use of CFHH 
and self- monitoring in particular (see above, #20) did not 
necessarily mean that self- reported subjective adherence 
and electronically captured objective adherence were 
well aligned (#28, online supplemental file 03, tables F 
and G). A post hoc paired comparison of subjective and 
objective adherence at 5 (±1) months (figure 3) suggests 
that higher adherers were more uniformly accurate in 
their understanding of their own adherence, whereas low 
adherers could be overly optimistic.
Intermediate outcomes
Item #34 of the logic model, treatment optimisation, is 
defined by NICE as, ‘a person- centred approach to safe 
and effective medicines use’ to ensure best outcomes.66 
Treatment optimisation is a service- level objective, which 
was beyond the scope of our patient- focused intervention 
but is the subject of related ongoing research (see Discus-
sion section). During interviews, RCT participants in the 
intervention arm described behaviours that would affect 
treatment optimisation, for instance taking holidays from 
their treatment. Levels of CF treatment adherence (#35) 
Figure 3 Objective versus subjective adherence at 5 (±1) 
months stratified by adherence.
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were 10% (95% CI: −5.2 to 25.2) higher in the interven-
tion arm (online supplemental file 06). We developed a 
number of theories about why some intervention patients 
did or did not increase their adherence (#35) during 
the analysis. In some cases the run charts illustrated, 
inline with Control Theory, the goal- directed nature of 
behaviour and how it is regulated by feedback control 
processes.67 For example, R01/39 and R01/49 seemed 
to show improvement shortly before planned face- to- face 
visits from interventionists (online supplemental file 01). 
R01/39, who seemed intrinsically motivated when inter-
viewed, sustained improvement in adherence beyond the 
trial period through what they described as positive inter-
action with the interventionist. Others, who seemed more 
extrinsically motivated in interviews (R01/49, R01/54, 
R01/48: see #17), did not sustain adherence, with charts 
suggesting an effortful, ‘all- or- nothing’ pattern. At base-
line, R02/07 had no well- established routine (CHAOS 
score of 10: online supplemental file 01), implying 
substantial self- regulatory effort to achieve higher adher-
ence. In their interview, this participant reported finding 
habit formation parts, such as goal- setting, helpful which 
may have enabled him to maintain high adherence with 
reduced effort, as measured by increased habit and 
reduced life chaos and barriers (change scores −5 and −3, 
respectively: online supplemental file 03, table F). Finally, 
it is important to understand that individual- level adher-
ence can be unstable over time (online supplemental 
file 01, see especially, R01/54, R01/48) highlighting 
the problem of assessing adherence as a ‘snapshot’ in 
a pretest/post- test analysis, rather than in a continuous 
assessment over time.
Several participants with low baseline adherence 
appeared to have responded well to the intervention. 
R01/40 had high motivation (online supplemental files 
01 and 03, table B), possibly due to the salience of a recent 
hospitalisation for IVAB treatment of an exacerbation. 
Click analytic data showed high engagement, with inde-
pendent access of the website and use of problem- solving 
tools. However, in other patients, case study run charts 
(online supplemental file 01) showed that measuring 
change in average objective adherence between baseline 
and 5 months sometimes masked periods of success in 
between (eg, R01/02, and R02/12). Without looking at 
adherence graphs, and only measuring objective adher-
ence at baseline and 5 months, this would have been 
missed (see Discussion section). Interview data offered 
some reasons for improved adherence. While R01/49 
had not made an action plan and their subjective adher-
ence was optimistic (online supplemental file 03, table 
F), their objective adherence increased from low to 
moderate over the trial period (online supplemental file 
01); their motivation also increased and self- reported 
barriers decreased (online supplemental file 03, table 
F), potentially through their high use of problem- solving 
modules and self- monitoring (online supplemental file 
03, table D). R01/02’s run chart also showed a period of 
improvement, ending after the last review visit (online 
supplemental file 01); nonetheless, reduced life chaos 
(online supplemental file 03, Table F) and interview data 
suggested an established routine and reduced barriers 
associated with intensive face- to- face therapist interaction 
and action/coping plans (online supplemental file 03, 
table D). The tailing off of adherence after the end of 
the trial in some case study participants may indicate that 
adherence remained effortful or participation in the trial 
was motivated by altruism not help- seeking (see quota-
tion from R01/48, above).
Modifications to the intervention
Online supplemental file 07 documents 14 technical 
changes that will be made for the full- scale RCT, based 
on the process evaluation findings, to CFHH (n=5), IT 
infrastructure (n=1) and to the interventionist training, 
manual and procedures (n=8). To prevent adherence 
data flatlines, nebulisers (#4) and 2net Hubs (#5) will be 
paired at the factory. Three changes to CFHH (#6) will 
make it easier for interventionists to view/edit prescrip-
tion data and to handle alternating treatment regimens 
(#3). Other changes to CFHH will include making 
graphs more easily interpretable and, based on interview 
data and PPI feedback, adding descriptions to videos. 
Changes to the interventionist manual (#8) will increase 
the emphasis on ‘active ingredients’, introduce interven-
tion triggers for reduced adherence or exacerbations and 
introduce new habit formation sessions. The need for 
increased numbers of protocolised intervention review 
sessions arose because, in the feasibility study, a focus 
on RCT recruitment targets gave interventionists inade-
quate time to deliver review visits (#18, #24), critical for 
updating personalised action plans (#25) and updating 
coping plans (#26). Training (#9) in the full- scale trial 
will be delivered as an intensive 1- week course, with more 
explicit focus on intervention fidelity, supported by new 
case study data and role plays to ensure baseline compe-
tency (#17).
DISCUSSION
The process evaluation identified elements of the inter-
vention which could be improved and 14 changes were 
documented. The complex intervention was developed 
using mixed- methods research with an interdisciplinary, 
person- centred and iterative approach.68–74 The mere 
usage of a digital behaviour change intervention may not 
indicate engagement or lead to desired outcomes;68 73 75–78 
there is no simple dose–response relationship.79 In fact, for 
those with low motivation and low confidence, evidence 
of non- adherence can be threatening.80 81 With different 
baseline motivation and life chaos, a population- level 
definition of ‘effective engagement’70 may be infeasible, 
but contextual and motivational data may still explain 
patterns observed in run charts.82 What may matter more 
than defining engagement is the correct assessment 
and tailoring of management to different psychosocial 
barriers.69 83–91 Our study suggests that digital systems 
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cannot replace, only complement, face- to- face interaction 
between health professionals and patients,92–95 potentially 
creating a sense of ‘accountability’ consistent with control 
theory.46 96 However, it is important to recognise that in 
the absence of objective adherence data, clinicians and 
patients will find it difficult to even begin to engage with 
behaviour change.
Chronic disease self- management is a complex and 
multifactorial problem and, we were unable to cover all 
of the analyses that many would consider relevant. For 
instance, although the intervention is meant to increase 
health literacy through education, we cannot rule out that 
baseline socioeconomic status, known to affect health 
literacy, outcomes and self- management,97–99 was not a 
factor. Another limitation of this study is that we inter-
viewed just over only one quarter of the pilot trial sample. 
Given a relatively homogeneous population, narrow, 
exploratory study aims and the use of established theory, 
14 interviews should be adequate to discern common 
perceptions and experiences.100 101 In the full- scale eval-
uation of this intervention (see last paragraph of this 
section), the process evaluation will involve a user accept-
ability survey of ~250 intervention users from 19 centres 
and face- to- face interviews with over 50 intervention users, 
interventionists and clinicians. As in many other process 
evaluations, we will use maximum variation sampling on 
sociodemographic characteristics and baseline adher-
ence, alongside triangulation, to minimise the risk of 
bias.102 Additionally, readers should be aware that small- 
scale feasibility work does not generalise in every regard 
when scaled up in larger scale studies.103 104 Finally, early 
health economic modelling of the cost- effectiveness,105 
was not updated as part of this feasibility work, but will be 
revisited in 2021 as part of the full- scale evaluation.
Our use of objective adherence measurement over-
comes the limitations of previous studies106 and confirms 
that subjective and objective adherence are poorly 
aligned.23 This process evaluation has succeeded in 
demonstrating that delivery of this intervention is possible 
in busy clinical settings; participant uptake was high and, 
with further development on the basis of these findings, 
the process of gathering objective adherence data and 
implementing it alongside a behavioural intervention is 
both possible and effective.
Given the known difficulties with nebuliser use among 
PWCF, interventions that can make it less effortful are 
important.107 In particular, healthy behaviours are better 
predicted by a patient’s level of automatic behavioural 
repetition than their beliefs or experiences, meaning 
a focus on increasing habit strength is critical for 
chronic disease self- management.108 Through delivery 
of intervention components designed to promote habit 
formation, we intend to reduce effort with the CFHH 
intervention. We are limited in drawing conclusions as to 
the impact of habit formation components of the inter-
vention from this analysis; this is mostly due to the limited 
time constraints of the feasibility study leaving insufficient 
opportunity for habit formation.109 However, there was 
some indication that habit components were useful and 
we have elsewhere demonstrated the importance of habit 
in high adherence.110 111 It has also been indicated that 
adherence interventions focusing on habit formation are 
the most effective.112
Successful habit formation will reduce burden by 
making sustained self- care automatic. The CFHH inter-
vention aims to deliver the fall in burden highlighted 
by the Lind alliance prioritisation exercise as the most 
important goal of CF research.
To date, there is little previous research showing the 
effects of giving patients access to their data, with respect 
to health outcomes and cost- effectiveness. Amidst the 
evidence that does exist, the research is generally poor 
and lacks information about context and implementa-
tion.113 114 Following modifications made to our complex 
intervention, the full- scale RCT across 19 UK centres 
(ISRCTN55504164) will provide high- quality evidence, 
indicating the impact of adherence data on sustained 
self- care. The full- scale RCT will include a further process 
evaluation and health- economic modelling. Further-
more, the CFHH Data Observatory (ISRCTN14464661) 
following on from the RCT will address the issue of how 
to embed the use of adherence data in routine practice 
for healthcare professionals.115–119 The sites involved in 
the reported pilot study have now transitioned into the 
Data Observatory, eventually to be joined by sites involved 
in the full- scale RCT. Data collected in the Data Obser-
vatory quality improvement project will be used in the 
development of generalisable theory and practical guid-
ance about the collaborative use of adherence data,120–122 
with a focus on optimising the use of healthcare resources 
and improving patient care.66 123 The Observatory will act 
as a platform for efficient trials,124 125 providing an oppor-
tunity to share processes and improvement activities to 
enable participating CF clinical research teams to meet 
the demands of future research.126
CONCLUSIONS
We have developed a theory- based complex intervention 
to help PWCF adhere to their medication and form habits 
of sustained self- care. The process evaluation identified 
potential sources of intervention failure and modifica-
tions have been made accordingly. With improved inter-
vention processes, it is feasible and acceptable to support 
sustained self- care via medication adherence through 
the application of behaviour change theory delivered 
through digital and human components.
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